Infection Prevention in Chronic Kidney Disease/Dialysis/Transplant

Abstract

Children with renal disorders including chronic glomerular conditions, chronic kidney disease, end-stage renal disease, and kidney transplant recipients have a higher infection risk. This review covers infection prevention in this population, with a focus on vaccination strategies.

Keywords

children - infection prevention - immunization - vaccines - chronic kidney disease - dialysis - kidney transplant - nephrotic syndrome - eculizumab

• References

• 1 McIntyre P, Craig JC. Prevention of serious bacterial infection in children with nephrotic syndrome. J Paediatr Child Health 1998; 34 (04) 314-317
• 2 Minimal change nephrotic syndrome in children: deaths during the first 5 to 15 years' observation. Report of the International Study of Kidney Disease in Children. Pediatrics 1984; 73 (04) 497-501
• 3 Anderson DC, York TL, Rose G, Smith CW. Assessment of serum factor B, serum opsonins, granulocyte chemotaxis, and infection in nephrotic syndrome of children. J Infect Dis 1979; 140 (01) 1-11
• 4 Ballow M, Kennedy III TL, Gaudio KM, Siegel NJ, McLean RH. Serum hemolytic factor D values in children with steroid-responsive idiopathic nephrotic syndrome. J Pediatr 1982; 100 (02) 192-196
• 5 McLean RH, Forsgren A, Björkstén B, Kim Y, Quie PG, Michael AF. Decreased serum factor B concentration associated with decreased opsonization of Escherichia coli in the idiopathic nephrotic syndrome. Pediatr Res 1977; 11 (08) 910-916
• 6 Gorensek MJ, Lebel MH, Nelson JD. Peritonitis in children with nephrotic syndrome. Pediatrics 1988; 81 (06) 849-856
• 7 MacHardy N, Miles PV, Massengill SF. , et al. Management patterns of childhood-onset nephrotic syndrome. Pediatr Nephrol 2009; 24 (11) 2193-2201
• 8 Nuorti JP, Whitney CG. ; Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59 ( RR-11) 1-18
• 9 Gipson DS, Massengill SF, Yao L. , et al. Management of childhood onset nephrotic syndrome. Pediatrics 2009; 124 (02) 747-757
• 10 Spika JS, Halsey NA, Fish AJ. , et al. Serum antibody response to pneumococcal vaccine in children with nephrotic syndrome. Pediatrics 1982; 69 (02) 219-223
• 11 Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins for persons with altered immunocompetence. MMWR Recomm Rep 1993; 42 ( RR-04(. 1-18
• 12 Poyrazoğlu HM, Düşünsel R, Gündüz Z, Patiroğlu T, Köklü S. Antibody response to influenza A vaccination in children with nephrotic syndrome. Pediatr Nephrol 2004; 19 (01) 57-60
• 13 Furth SL, Arbus GS, Hogg R, Tarver J, Chan C, Fivush BA. ; Southwest Pediatric Nephrology Study Group. Varicella vaccination in children with nephrotic syndrome: a report of the Southwest Pediatric Nephrology Study Group. J Pediatr 2003; 142 (02) 145-148
• 14 Loirat C, Fakhouri F, Ariceta G. , et al; HUS International. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2016; 31 (01) 15-39
• 15 Figueroa JE, Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 1991; 4 (03) 359-395
• 16 Ram S, Lewis LA, Rice PA. Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev 2010; 23 (04) 740-780
• 17 Cofiell R, Kukreja A, Bedard K. , et al. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood 2015; 125 (21) 3253-3262
• 18 Benamu E, Montoya JG. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis 2016; 29 (04) 319-329
• 19 Legendre CM, Licht C, Muus P. , et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368 (23) 2169-2181
• 20 Cohn AC, MacNeil JR, Clark TA. , et al; Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62 ( RR-02). 1-28
• 21 Naqvi SB, Collins AJ. Infectious complications in chronic kidney disease. Adv Chronic Kidney Dis 2006; 13 (03) 199-204
• 22 Chonchol M. Neutrophil dysfunction and infection risk in end-stage renal disease. Semin Dial 2006; 19 (04) 291-296
• 23 Vaziri ND, Pahl MV, Crum A, Norris K. Effect of uremia on structure and function of immune system. J Ren Nutr 2012; 22 (01) 149-156
• 24 Flynn JT, Frisch K, Kershaw DB, Sedman AB, Bunchman TE. Response to early measles-mumps-rubella vaccination in infants with chronic renal failure and/or receiving peritoneal dialysis. Adv Perit Dial 1999; 15: 269-272
• 25 Neu AM, Fivush BA. Immunizations for pediatric dialysis patients. Adv Ren Replace Ther 2000; 7 (03) 239-246
• 26 Furth SL, Hogg RJ, Tarver J, Moulton LH, Chan C, Fivush BA. Southwest Pediatric Nephrology Study Group. Varicella vaccination in children with chronic renal failure. A report of the Southwest Pediatric Nephrology Study Group. Pediatr Nephrol 2003; 18 (01) 33-38
• 27 Committee on Infectious Diseases; American Academy of Pediatrics. Recommended childhood and adolescent immunization schedule-United States, 2015. Pediatrics 2015; 135 (02) 396-397
• 28 Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001; 50 ( RR-05). 1-43
• 29 Watkins SL, Alexander SR, Brewer ED. , et al; Southwest Pediatric Nephrology Study Group. Response to recombinant hepatitis B vaccine in children and adolescents with chronic renal failure. Am J Kidney Dis 2002; 40 (02) 365-372
• 30 Sheth RD, Peskin MF, Du XL. The duration of hepatitis B vaccine immunity in pediatric dialysis patients. Pediatr Nephrol 2014; 29 (10) 2029-2037
• 31 Furth SL, Neu AM, McColley SA, Case B, Steinhoff M, Fivush B. Immune response to influenza vaccination in children with renal disease. Pediatr Nephrol 1995; 9 (05) 566-568
• 32 Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 Influenza Season. MMWR Morb Mortal Wkly Rep 2015; 64 (30) 818-825
• 33 Rubin LG, Levin MJ, Ljungman P. , et al; Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58 (03) 309-318
• 34 Danziger-Isakov L, Kumar D. AST Infectious Diseases Community of Practice. Vaccination in solid organ transplantation. Am J Transplant 2013; 13 (Suppl. 04) 311-317
• 35 Esposito S, Mastrolia MV, Prada E, Pietrasanta C, Principi N. Vaccine administration in children with chronic kidney disease. Vaccine 2014; 32 (49) 6601-6606
• 36 Gangappa S, Kokko KE, Carlson LM. , et al. Immune responsiveness and protective immunity after transplantation. Transpl Int 2008; 21 (04) 293-303
• 37 Abuali MM, Arnon R, Posada R. An update on immunizations before and after transplantation in the pediatric solid organ transplant recipient. Pediatr Transplant 2011; 15 (08) 770-777
• 38 Ladd JM, Karkazis K, Magnus D. Parental refusal of vaccination and transplantation listing decisions: a nationwide survey. Pediatr Transplant 2013; 17 (03) 244-250
• 39 Benden C, Danziger-Isakov LA, Astor T. , et al. Variability in immunization guidelines in children before and after lung transplantation. Pediatr Transplant 2007; 11 (08) 882-887
• 40 Lee DH, Boyle SM, Malat G, Sharma A, Bias T, Doyle AM. Low rates of vaccination in listed kidney transplant candidates. Transpl Infect Dis 2016; 18 (01) 155-159
• 41 Chon WJ, Kadambi PV, Harland RC. , et al. Changing attitudes toward influenza vaccination in U.S. kidney transplant programs over the past decade. Clin J Am Soc Nephrol 2010; 5 (09) 1637-1641
• 42 Smith JG, Metzger NL. Evaluation of pneumococcal vaccination rates after vaccine protocol changes and nurse education in a tertiary care teaching hospital. J Manag Care Pharm 2011; 17 (09) 701-708
• 43 Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (Suppl. 03) S1-S155
• 44 Struijk GH, Lammers AJ, Brinkman RJ. , et al. Immunization after renal transplantation: current clinical practice. Transpl Infect Dis 2015; 17 (02) 192-200
• 45 Vilchez RA, McCurry K, Dauber J. , et al. Influenza virus infection in adult solid organ transplant recipients. Am J Transplant 2002; 2 (03) 287-291
• 46 Dos Santos G, Haguinet F, Cohet C. , et al. Risk of solid organ transplant rejection following vaccination with seasonal trivalent inactivated influenza vaccines in England: a self-controlled case-series. Vaccine 2016; 34 (31) 3598-3606
• 47 Vermeiren P, Aubert V, Sugamele R. , et al. Influenza vaccination and humoral alloimmunity in solid organ transplant recipients. Transpl Int 2014; 27 (09) 903-908
• 48 Mauch TJ, Crouch NA, Freese DK, Braunlin EA, Dunn DL, Kashtan CE. Antibody response of pediatric solid organ transplant recipients to immunization against influenza virus. J Pediatr 1995; 127 (06) 957-960
• 49 Nailescu C, Xu X, Zhou H. , et al. Influenza vaccine after pediatric kidney transplant: a Midwest Pediatric Nephrology Consortium study. Pediatr Nephrol 2011; 26 (03) 459-467
• 50 Salles MJ, Sens YA, Boas LS, Machado CM. Influenza virus vaccination in kidney transplant recipients: serum antibody response to different immunosuppressive drugs. Clin Transplant 2010; 24 (01) E17-E23
• 51 Martinez-Atienza J, Rosso-Fernández C, Roca C. , et al; TRANSGRIPE 1-2 Study Group. Efficacy and safety of a booster dose of influenza vaccination in solid organ transplant recipients, TRANSGRIPE 1-2: study protocol for a multicenter, randomized, controlled clinical trial. Trials 2014; 15: 338
• 52 Pérez-Romero P, Bulnes-Ramos A, Torre-Cisneros J. , et al; Influenza Vaccine in Solid Organ Transplant Recipient Study Group, Spanish Network of Research in Infectious Diseases (REIPI-GESITRA); Influenza Vaccine in Solid Organ Transplant Recipient Study Group Spanish Network of Research in Infectious Diseases REIPI-GESITRA. Influenza vaccination during the first 6 months after solid organ transplantation is efficacious and safe. Clin Microbiol Infect 2015; 21 (11) 1040.e11-1040.e18
• 53 Friedrich P, Sattler A, Müller K, Nienen M, Reinke P, Babel N. Comparing humoral and cellular immune response against HBV vaccine in kidney transplant patients. Am J Transplant 2015; 15 (12) 3157-3165
• 54 Moal V, Motte A, Vacher-Coponat H, Tamalet C, Berland Y, Colson P. Considerable decrease in antibodies against hepatitis B surface antigen following kidney transplantation. J Clin Virol 2015; 68: 32-36
• 55 Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet 2000; 355 9203 561-565
• 56 Leonardi S, Praticò AD, Lionetti E, Spina M, Vitaliti G, La Rosa M. Intramuscular vs intradermal route for hepatitis B booster vaccine in celiac children. World J Gastroenterol 2012; 18 (40) 5729-5733
• 57 Shouval D, Roggendorf H, Roggendorf M. Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine. Med Microbiol Immunol (Berl) 2015; 204 (01) 57-68
• 58 Kanaan N, Kabamba B, Maréchal C. , et al. Significant rate of hepatitis B reactivation following kidney transplantation in patients with resolved infection. J Clin Virol 2012; 55 (03) 233-238
• 59 Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2013; 62 (25) 521-524
• 60 Tran L, Hébert D, Dipchand A, Fecteau A, Richardson S, Allen U. Invasive pneumococcal disease in pediatric organ transplant recipients: a high-risk population. Pediatr Transplant 2005; 9 (02) 183-186
• 61 Barton M, Wasfy S, Dipchand AI. , et al. Seven-valent pneumococcal conjugate vaccine in pediatric solid organ transplant recipients: a prospective study of safety and immunogenicity. Pediatr Infect Dis J 2009; 28 (08) 688-692
• 62 Lindemann M, Heinemann FM, Horn PA, Witzke O. Immunity to pneumococcal antigens in kidney transplant recipients. Transplantation 2010; 90 (12) 1463-1467
• 63 Broeders EN, Wissing KM, Ghisdal L. , et al. Large decrease of anti-tetanus anatoxin and anti-pneumococcal antibodies at one year after renal transplantation. Clin Nephrol 2013; 79 (04) 313-317
• 64 Lindemann M, Heinemann FM, Horn PA, Witzke O. Long-term response to vaccination against pneumococcal antigens in kidney transplant recipients. Transplantation 2012; 94 (01) 50-56
• 65 Kumar D, Welsh B, Siegal D, Chen M, Humar A. Immunogenicity of pneumococcal vaccine in renal transplant recipients--three year follow-up of a randomized trial. Am J Transplant 2007; 7 (03) 633-638
• 66 Malone K, Clark S, Palmer JA. , et al. A quality improvement initiative to increase pneumococcal vaccination coverage among children after kidney transplant. Pediatr Transplant 2016; 20 (06) 783-789
• 67 Hinten F, Meeuwis KA, van Rossum MM, de Hullu JA. HPV-related (pre)malignancies of the female anogenital tract in renal transplant recipients. Crit Rev Oncol Hematol 2012; 84 (02) 161-180
• 68 de Sanjose S, Quint WG, Alemany L. , et al; Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11 (11) 1048-1056
• 69 Brown DR, Garland SM, Ferris DG. , et al. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay. Hum Vaccin 2011; 7 (02) 230-238
• 70 Kumar D, Unger ER, Panicker G, Medvedev P, Wilson L, Humar A. Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients. Am J Transplant 2013; 13 (09) 2411-2417
• 71 Gomez-Lobo V, Whyte T, Kaufman S, Torres C, Moudgil A. Immunogenicity of a prophylactic quadrivalent human papillomavirus L1 virus-like particle vaccine in male and female adolescent transplant recipients. Pediatr Transplant 2014; 18 (03) 310-315
• 72 Nelson DR, Neu AM, Abraham A, Amaral S, Batisky D, Fadrowski JJ. Immunogenicity of human papillomavirus recombinant vaccine in children with CKD. Clin J Am Soc Nephrol 2016; 11 (05) 776-784